GeneDx Holdings Corp.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: GeneDx Holdings Corp. |
| Ticker: | Ticker: WGS |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
On May 4, 2026, GeneDx released its first quarter 2026 financial results, revealing earnings per share of ($0.28), and a $57.5 million loss from operations. The Company also lowered its 2026 revenue guidance by approximately $65 million at the midpoint. GeneDx revealed it had “lower-than-expected blended average reimbursement rate for exome and genome” and “softer-than-expected performance from [its] noncore business lines” including Fabric Genomics. The Company also took a $31.3 million write-down related to the goodwill and intangible assets of its Fabric Genomics reporting unit, “primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.” On this news, the price of GeneDx shares declined by $33.42 per share, or approximately 50%, from $67.93 per share on May 4, 2026 to close at $34.51 on May 5, 2026.
On May 4, 2026, GeneDx released its first quarter 2026 financial results, revealing earnings per share of ($0.28), and a $57.5 million loss from operations. The Company also lowered its 2026 revenue guidance by approximately $65 million at the midpoint. GeneDx revealed it had “lower-than-expected blended average reimbursement rate for exome and genome” and “softer-than-expected performance from [its] noncore business lines” including Fabric Genomics. The Company also took a $31.3 million write-down related to the goodwill and intangible assets of its Fabric Genomics reporting unit, “primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.” On this news, the price of GeneDx shares declined by $33.42 per share, or approximately 50%, from $67.93 per share on May 4, 2026 to close at $34.51 on May 5, 2026.